Argen-X N.V. (Argenx). (4/24/17). "Press Release: Argenx Files Registration Statement for a Proposed Public Offering in the United States". Breda & Ghent.

	Region	United States (USA)
	Organisation	Argen-X N.V. (Argenx) (Euronext + Nasdaq: ARGX)
	Today	Argenx SE (Euronext + Nasdaq: ARGX)
	Group	Argenx (Argen-X) (Group)
	Organisation 2	Nasdaq
	Group	Nasdaq OMX (Group)
	Product	investment banking
	Product 2	SIMPLE Antibody™ discovery platform
	Index term	Argenx–SEVERAL: investment, 201704–201705 US IPO $114.7m with 5.865m+879.75k ADSs at $17/ADS + new listing at Nasdaq
	Person	Comijn, Joke (Argen-X 201704 Corp Communications Manager)
	Person 2	DelGiacco, Beth (Argenx 201806– VP Investor Relations before Stern IR)

argenx N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that it filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission for a proposed public offering in the United States of its American Depositary Shares (ADSs) representing ordinary shares. All ADSs to be sold in the offering will be offered by argenx. The offering is subject to market and other conditions, including the effectiveness of the above-referenced registration statement. argenx’s ordinary shares are currently listed on Euronext Brussels and argenx has made an application to have its ADSs listed on the NASDAQ Stock Market under the symbol “ARGX”.

Cowen and Company and Piper Jaffray & Co. are acting as joint bookrunning managers for the proposed offering, and JMP Securities and Wedbush PacGrow are acting as co-managers. Kempen & Co is acting as argenx’s advisor in connection with the proposed offering.

The securities referred to in this release are to be offered only by means of a prospectus. When available, copies of the preliminary prospectus can be obtained from Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by telephone at (631) 274-2806 or by fax at (631) 254-7140 or from Piper Jaffray & Co., Attn: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55403, or by telephone at (800)747-3924, or by email at prospectus@pjc.com.

A registration statement relating to and describing the terms of the offering has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. The securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About argenx

argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE Antibody™ Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates.

For further information, please contact:

Joke Comijn, Corporate Communications Manager
+32 (0)477 77 29 44
+32 (0)9 310 34 19
info@arGEN-X.com

Beth DelGiacco (US IR)
Stern Investor Relations
+1 212 362 1200
beth@sternir.com

Forward-looking Statements

The contents of this announcement include statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes”, “estimates”, “anticipates”, “expects”, “intends”, “may”, “will”, or “should”, and include statements argenx makes concerning the intended results of its strategy, including argenx’s advancement of, and anticipated clinical development and regulatory milestones and plans related to, ARGX-115. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx’s actual results may differ materially from those predicted by the forward-looking statements. argenx undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

Record changed: 2023-06-05